Effect of Antiretroviral Therapy Including Lopinavir/Ritonavir or Efavirenz on Etonogestrel-Releasing Implant Pharmacokinetics in HIV-Positive Women

@article{Vieira2014EffectOA,
  title={Effect of Antiretroviral Therapy Including Lopinavir/Ritonavir or Efavirenz on Etonogestrel-Releasing Implant Pharmacokinetics in HIV-Positive Women},
  author={C. Vieira and M. V. Bahamondes and R. M. de Souza and M. B. Brito and Tatiana R Rocha Prandini and E. Amaral and L. Bahamondes and G. Duarte and S. Quintana and Carolina Scaranari and R. Ferriani},
  journal={JAIDS Journal of Acquired Immune Deficiency Syndromes},
  year={2014},
  volume={66},
  pages={378–385}
}
  • C. Vieira, M. V. Bahamondes, +8 authors R. Ferriani
  • Published 2014
  • Medicine
  • JAIDS Journal of Acquired Immune Deficiency Syndromes
    • Objective:Data on the interaction between the etonogestrel (ENG) implant and antiretroviral therapy are lacking. We evaluated the effect of 2 highly active antiretroviral therapy (HAART) regimens (1 including efavirenz and the other ritonavir-boosted lopinavir) on the pharmacokinetic (PK) parameters of an ENG-releasing implant in HIV-positive women. Design:Prospective nonrandomized PK study. Methods:Forty-five HIV-positive women who desired to use ENG implants were included: 15 had received… CONTINUE READING
    View on Wolters Kluwer
    ncbi.nlm.nih.gov
    59 Citations
    Highly Influencial Citations
    2
    Background Citations
    17
    Methods Citations
    3
    Results Citations
    3
    59 Citations
    Citation Type

    Citation Type

    Effect of Coadministration of Etonogestrel Implant and AntiretroviralTherapies Containing Efavirenz or Lopinavir/Ritonavir on the Metabolismof Women Living with HIV/AIDS
    Bleeding patterns of HIV-infected women using an etonogestrel-releasing contraceptive implant and efavirenz-based or lopinavir/ritonavir-based antiretroviral therapy
    • 2
    Efavirenz decreases etonogestrel exposure: a pharmacokinetic evaluation of implantable contraception with antiretroviral therapy
    • 28
    Effect of patient genetics on etonogestrel pharmacokinetics when combined with efavirenz or nevirapine ART.
    • 2
    Etonogestrel concentrations among contraceptive implant users in Botswana using and not using dolutegravir-based antiretroviral therapy.
    • 1
    Antiretroviral therapy and vaginally administered contraceptive hormones: a three-arm, pharmacokinetic study.
    • 5
    • PDF
    Pharmacogenetic interactions between antiretroviral drugs and vaginally administered hormonal contraceptives
    • 1
    High Variability of Hormonal Levels and No Clinically Relevant Interaction Between Ethinyl Estradiol, Desogestrel and Lopinavir/Ritonavir in a Small Sample of HIV-positive Adolescents
    • 7
    Physiologically based pharmacokinetic modelling prediction of the effects of dose adjustment in drug–drug interactions between levonorgestrel contraceptive implants and efavirenz-based ART
    • 10
    • PDF
    Pharmacogenetics of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in resource-limited settings: Influence on antiretroviral therapy response and concomitant anti-tubercular, antimalarial and contraceptive treatments.
    • G. Russo, G. Paganotti, +4 authors L. Gustafsson
    • Biology, Medicine
    • Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases
    • 2016
    • 15

    References

    SHOWING 1-10 OF 46 REFERENCES
    The effect of efavirenz on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy HIV-negative women.
    • 56
    • PDF
    Variations of CYP3A activity induced by antiretroviral treatment in HIV-1 infected patients
    • 65
    • PDF
    Pharmacokinetic Interactions between the Hormonal Emergency Contraception, Levonorgestrel (Plan B), and Efavirenz
    • 56
    • PDF
    Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers.
    • 174
    Lopinavir/Ritonavir Induces the Hepatic Activity of Cytochrome P450 Enzymes CYP2C9, CYP2C19, and CYP1A2 But Inhibits the Hepatic and Intestinal Activity of CYP3A as Measured by a Phenotyping Drug Cocktail in Healthy Volunteers
    • 164
    Early contraceptive failure of Implanon® in an HIV-seropositive patient on triple antiretroviral therapy with zidovudine, lamivudine and efavirenz
    • 40
    • PDF
    The role of CYP2C and CYP3A in the disposition of 3-keto-desogestrel after administration of desogestrel.
    • 22
    ABT-378, a Highly Potent Inhibitor of the Human Immunodeficiency Virus Protease
    • 403
    • PDF
    Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study.
    • 405
    • PDF
    Contraception for the HIV-Positive Woman: A Review of Interactions between Hormonal Contraception and Antiretroviral Therapy
    • 80
    • Highly Influential
    • PDF